Fluocinolone AcetonideCAS# 67-73-2 |
- Etifoxine
Catalog No.:BCC1560
CAS No.:21715-46-8
- Etomidate
Catalog No.:BCC1150
CAS No.:33125-97-2
- Etifoxine hydrochloride
Catalog No.:BCC1561
CAS No.:56776-32-0
- Acamprosate calcium
Catalog No.:BCC1327
CAS No.:77337-73-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 67-73-2 | SDF | Download SDF |
| PubChem ID | 6215 | Appearance | Powder |
| Formula | C24H30F2O6 | M.Wt | 452.4999 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 31 mg/mL (68.51 mM) *"≥" means soluble, but saturation unknown. | ||
| SMILES | CC1(OC2CC3C4CC(C5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)F)C | ||
| Standard InChIKey | FEBLZLNTKCEFIT-VSXGLTOVSA-N | ||
| Standard InChI | InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Fluocinolone Acetonide Dilution Calculator
Fluocinolone Acetonide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2099 mL | 11.0497 mL | 22.0995 mL | 44.1989 mL | 55.2486 mL |
| 5 mM | 0.442 mL | 2.2099 mL | 4.4199 mL | 8.8398 mL | 11.0497 mL |
| 10 mM | 0.221 mL | 1.105 mL | 2.2099 mL | 4.4199 mL | 5.5249 mL |
| 50 mM | 0.0442 mL | 0.221 mL | 0.442 mL | 0.884 mL | 1.105 mL |
| 100 mM | 0.0221 mL | 0.1105 mL | 0.221 mL | 0.442 mL | 0.5525 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fluocinolone Acetonide
- 5-Hydroxymethylfurfural
Catalog No.:BCN4226
CAS No.:67-47-0
- Furazolidone
Catalog No.:BCC8988
CAS No.:67-45-8
- EGTA
Catalog No.:BCC7491
CAS No.:67-42-5
- Thiamine hydrochloride
Catalog No.:BCN2225
CAS No.:67-03-8
- Tianeptine
Catalog No.:BCC1999
CAS No.:66981-73-5
- Beta-Belladonnine
Catalog No.:BCN1893
CAS No.:6696-63-5
- α-Conotoxin PIA
Catalog No.:BCC5976
CAS No.:669050-68-4
- 1,2-O-Isopropylidene-beta-D-fructopyranose
Catalog No.:BCN1383
CAS No.:66900-93-4
- Talniflumate
Catalog No.:BCC7391
CAS No.:66898-62-2
- H-D-Leu-OBzl.HCl
Catalog No.:BCC2682
CAS No.:66866-69-1
- Halobetasol Propionate
Catalog No.:BCC4664
CAS No.:66852-54-8
- LDN 57444
Catalog No.:BCC2087
CAS No.:668467-91-2
- Dicyclomine HCl
Catalog No.:BCC3762
CAS No.:67-92-5
- Vitamin D3
Catalog No.:BCN2186
CAS No.:67-97-0
- Gliotoxin
Catalog No.:BCN3894
CAS No.:67-99-2
- Anthriscusin
Catalog No.:BCN3533
CAS No.:67008-16-6
- Methyl isovanillate
Catalog No.:BCN7960
CAS No.:6702-50-7
- 3,4-Dihydroxy-2-methoxyxanthone
Catalog No.:BCN7631
CAS No.:6702-55-2
- Crenolanib (CP-868596)
Catalog No.:BCC3671
CAS No.:670220-88-9
- Ohchinin
Catalog No.:BCN4601
CAS No.:67023-80-7
- Ohchinin acetate
Catalog No.:BCN4220
CAS No.:67023-81-8
- Pepluanin A
Catalog No.:BCN4221
CAS No.:670257-89-3
- Trichophydine
Catalog No.:BCN1781
CAS No.:67031-54-3
- Datumetine
Catalog No.:BCN1930
CAS No.:67078-20-0
Real-Life ILUVIEN (Fluocinolone Acetonide) Case Study: Rapid Drying of the Macula and Improved Vision within 2 Years after Therapy Initiation.[Pubmed:28203186]
Case Rep Ophthalmol. 2016 Dec 28;7(3):301-307.
IMPORTANCE: A case showing sustained structural and functional responses 2 years after a single treatment with ILUVIEN (0.2 microg/day Fluocinolone Acetonide, FAc) despite suboptimal responses to ranibizumab. OBSERVATIONS: A 68-year-old female patient with diabetic macular oedema (DME) from type 2 diabetes mellitus was first diagnosed in October 2010 and had a baseline visual acuity (VA) of 46 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye. Central foveal thickness (CFT) was 712 microns. The patient was treated with 11 intravitreal injections of ranibizumab (5 in combination with a small-interfering RNA agent), and by March 2014, VA and CFT were largely unchanged (55 ETDRS letters and 774 microns). The patient was treated with ILUVIEN as she had a pseudophakic lens and a clearly suboptimal response to the prior therapy with ranibizumab. An implant releasing FAc at a dosage of 0.2 microg/day was administered in March 2014, and the optical coherence tomography indicated that the macula was dry after 7 days (CFT was below 300 microns). This was sustained at 6, 12, and 24 months after the treatment. VA improved by 5 letters within 7 days and by 15 letters within 14 days, and this was maintained after 24 months. Throughout the duration of this study, the intraocular pressure was
Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN((R))): A Review in Diabetic Macular Edema.[Pubmed:28283896]
Drugs. 2017 Apr;77(5):575-583.
Fluocinolone Acetonide intravitreal implant 0.19 mg (ILUVIEN((R))) is a nonbiodegradable, injectable, corticosteroid implant that is approved in several countries, including the USA, for the treatment of diabetic macular edema (DME). ILUVIEN((R)) releases Fluocinolone Acetonide at an initial rate of 0.25 microg/day (average rate 0.2 microg/day) and lasts 36 months. In the two pooled pivotal FAME trials in patients with DME previously treated with macular laser photocoagulation, Fluocinolone Acetonide intravitreal implant 0.2 microg/day was significantly more effective than sham injection with respect to the proportion of patients with an improvement from baseline in best-corrected visual acuity of >/=15 letters at 24 months (primary endpoint). This therapeutic effect was maintained at 36 months. The implant also significantly decreased foveal thickness at 24 months. FAME study results are broadly supported by real-world studies in patients with chronic DME considered insufficiently responsive to available therapies. Consistent with corticosteroid class-specific adverse events, cataract and elevated intraocular pressure (IOP) were the most common adverse events with the Fluocinolone Acetonide intravitreal implant. Raised IOP was treated with medications in most patients, with <5% requiring incisional IOP-lowering surgery. In the USA, Fluocinolone Acetonide intravitreal implant should be used only in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant increase in IOP. Available data indicate that Fluocinolone Acetonide intravitreal implant 0.19 mg is a useful option for the treatment of DME in these patients.
Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 microg/d intravitreal implant: real-world UK experience.[Pubmed:28165610]
Eur J Ophthalmol. 2017 May 11;27(3):357-362.
PURPOSE: To conduct an observational, multicenter study to evaluate real-world clinical efficacy and safety of the 0.2 microg/day Fluocinolone Acetonide (FAc) implant in the treatment of patients with chronic diabetic macular edema (DME) in 3 large hospital ophthalmology departments in the United Kingdom. METHODS: Fluocinolone Acetonide implants were inserted into the study eyes following a suitable washout period; phakic eyes received FAc implant following cataract surgery. Follow-up visits took place 2-4 weeks postinjection and then at 3, 6, and 12 months; change in central macular thickness (CMT) from baseline was measured by optical coherence tomography and best-corrected visual acuity (BCVA) was also assessed. Adverse events and changes in intraocular pressure (IOP) were recorded in order to evaluate the safety profile for the FAc implant. RESULTS: Improvements in BCVA and CMT were observed from 3 months and sustained for the duration of observation. At 12 months, the overall mean change from baseline CMT was -126 mum and mean increase in BCVA from baseline was 5.1 letters. Increases in IOP following FAc implant were easily managed with IOP-lowering medication. Implant migration into the anterior chamber occurred in 2 eyes where prior vitrectomy had resulted in a posterior capsule defect; this was rectified and resolved. CONCLUSIONS: The results of this study provide further efficacy and safety profile data for FAc implant treatment of chronic DME in a real-world clinical setting; the FAc implant appears to be a valuable therapeutic approach for patients with chronic DME who have suboptimal response to other treatment options.
